Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that by
the year 2000, 66.8 million people will be affected, of whom 6.7 million will be blind in both …

Topical β-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve
endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of …

Written by experts in the field, this comprehensive resource offers valuable information on
the practical uses of drugs in primary eye care. Discussions of the pharmacology of ocular …

β-Adrenoceptor blocking agents (β-blockers) have been established as therapeutics for
treatment of patients with hypertension, ischemic heart diseases, chronic heart failure …

In the twenty years since beta-blockers were proposed for treatment of glaucoma, use of
topical timolol has increased to account for 70% of all glaucoma medications used. The …

Despite its apparent easy accessibility, the eye is, in fact, well protected against the
absorption of foreign materials, including therapeutic agents, by the eyelids, by the tearflow …

Objective: To compare the cardiovascular, pulmonary, and ocular hypotensive effects of
0.2% brimonidine tartrate with those of 0.5% timolol maleate, 0.25% betaxolol suspension …

In a double-masked study, 40 patients with primary open-angle glaucoma were randomly
assigned to treatment with betaxolol 0.5% or timolol 0.5% in both eyes twice daily. Visual …

Glaucoma is the leading cause of blindness in the United States. It is estimated that two
million Americans have glaucoma and that the incidence of the disease in individuals aged …

Es ist das Verdienst von Professor Günter K. Krieglstein, das weltweit verwendete
Standardwerk über Glaukome von M. Bruce Shields ins Deutsche übersetzt und im Hinblick …